Related Experiment Videos
Assessment of left ventricular hypertrophy in patients with essential hypertension
1Clinical Experimental Research Laboratory, Sahlgrenska University Hospital/Ostra, Göteborg University, Sweden.
Insights
Electrocardiogram (ECG) criteria can accurately screen for left ventricular hypertrophy (LVH) in hypertensive patients. ECG is a cost-effective alternative to echocardiography for assessing LVH progression.
Area of Science:
- Cardiology
- Diagnostic Imaging
- Hypertension Management
Background:
- Left ventricular hypertrophy (LVH) is a significant cardiovascular risk indicator in hypertensive patients.
- Accurate diagnosis of LVH is crucial for patient prognosis and management.
- Current diagnostic methods include echocardiography and electrocardiography (ECG).
Purpose of the Study:
- To evaluate the diagnostic performance of ECG criteria for screening left ventricular hypertrophy in hypertensive individuals.
- To compare the effectiveness of ECG-based assessment with echocardiography for LVH detection.
Main Methods:
- Review of recently developed and combined ECG criteria for LVH assessment.
- Analysis of diagnostic accuracy, sensitivity, and specificity of ECG criteria (orthogonal-lead time-voltage, Sokolow-Lyon, Cornell Product).
- Comparison with echocardiographic examination for LVH evaluation.
Main Results:
- ECG screening can accurately estimate LVH in a majority of hypertensive patients.
- Orthogonal criteria show high sensitivity (81% in women, 71% in men) at 98% specificity.
- Combined Cornell Product or Sokolow-Lyon criteria offer 68% sensitivity at 96.6% specificity.
Conclusions:
- ECG-based LVH assessment is a viable and cost-effective screening tool for hypertensive patients.
- ECG allows for monitoring LVH progression or regression due to its widespread availability.
- Echocardiography offers superior sensitivity and additional risk information but ECG remains a practical alternative.
Abstract:
By virtue of its potency as a cardiovascular risk indicator, the presence of left ventricular hypertrophy (LVH) in a patient with hypertension deserves serious attention and make its diagnosis a clinical priority. In view of its prognostic impact, an argument could be made for routine assessment of this intermediate endpoint in each patient with essential hypertension. Two diagnostic approaches are available for screening evaluation of hypertensive patients; either a limited echocardiographic examination or an ECG-based LVH assessment. Recently developed new or combined criteria have significantly improved the diagnostic performance of ECG criteria, and evolving data show that accurate estimation of LVH can be performed by ECG screening in a majority of patients. At present, ECG evaluation based either on sex-specific orthogonal-lead time-voltage criteria or on the combined standard 12-lead criteria of Sokolow-Lyon (sum of S in V1 and R in V5 or V6) or Cornell Product (product of sum of R in aVL and S in V3 + 6 mm in females and QRS duration) demonstrates the best overall diagnostic accuracy. With orthogonal criteria, the sensitivity is 81% in women and 71% in men at a matched 98% specificity. The corresponding overall sensitivity of the combined Cornell Product or Sokolow-Lyon criteria is reported to be 68% at a specificity of 96.6%. What speaks in favour of the echocardiographic approach is its superior sensitivity and the possibility of gaining additional potential risk information associated with the geometric pattern of the LVH. However, its general availability makes electrocardiography a cost-effective diagnostic alternative with which to follow the progression or regression of LVH in hypertensive patients.